We still don't know how to taper glucocorticoids in rheumatoid arthritis, and we can do better

Journal of Rheumatology

Volumn 40, Issue 10, 2013, Pages 1646-1649

  Volkmann, Elizabeth R ^a   Rezai, Shadi ^a   Tarp, Simon ^b   Woodworth, Thasia G ^a   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Parker Institute   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; PLACEBO; PREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

AGE; ATHEROSCLEROSIS; CUSHINGOID SYNDROME; DIABETES MELLITUS; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; LOW DRUG DOSE; MYOPATHY; OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN FRAGILITY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS;

EID: 84885126979     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130019     Document Type: Review

References (19)

1. Criswell LA, Saag KG, Sems KM, Welch V, Shea B, Wells G, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev 2000;2:CD001158.
2. Kirwan JR, Bijlsma JWJ, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in RA [review]. Cochrane Database Syst Rev 2007;1:CD006356.
3. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55:420-6.
4. Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: Prevalence, predictors, correlates, and outcomes. J Rheumatol 2007;34:696-705.
5. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-4.
6. Kirwan JR, Hickey SH, Hallgren R, Mielants H, Bjorck E, Persson T, et al. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:1415-21.
7. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Higgins JPT, Green S, editors. [Internet. Accessed May 24, 2013.] Available from: www.cochrane-handbook.org
8. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
9. Tengstrand B, Larsson E, Klareskog L, Hafstrom I. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: Effects on inflammation and bone mineral density. Scand J Rheumatol 2007;36:351-8.
10. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized controlled trial. Arthritis Rheum 2005;52:3381-90.
11. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 2008;67:656-63.
12. Pincus T, Swearingen CJ, Luta G, Sokka T. Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomized, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009;68:1715-20.
13. Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol 1998;37:930-6.
14. Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003;48:1493-9.
15. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65:753-9.
16. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-yr extension study. Ann Rheum Dis 2009;68:1580-4.
17. Seror R, Dougados M, Gossec L. Glucocorticoid sparing effect of tumor necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 2009;27:807-13.
18. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
19. Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth TG, Alten R, Pohl C, et al. Identifying core domains to assess flare in rheumatoid arthritis: An OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012;71:1855-60.